<p>Backed by a $75m raise, Infinimmune targets cytokine cascades in skin aging – with an eye on systemic immunosenescence. Infinimmune has closed a $75 million Series A financing round to advance a pipeline of human-derived monoclonal antibodies toward clinical trials. Co-led by Regeneron Ventures and </p>